Clinical application of a cancer genomic profiling assay to guide precision medicine decisions

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

(2016) J. Madore et al.   CLINICAL CANCER RESEARCH

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

(2016) Vivek Asati et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine

(2016) Masayuki Nagahashi et al.   Genome Medicine

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

(2016) Gerald S. Falchook et al.   Journal for ImmunoTherapy of Cancer

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

(2016) Giuseppe V. Masucci et al.   Journal for ImmunoTherapy of Cancer

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

(2016) Claud Grigg et al.   Journal for ImmunoTherapy of Cancer

Advances in Cancer Immunotherapy in Solid Tumors

(2016) Smitha Menon et al.   Cancers

Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response

(2016) Junhun Cho et al.   Journal of Gastric Cancer

Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants

(2015) Takeru Chigira et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A survey of tandem repeat instabilities and associated gene expression changes in 35 colorectal cancers

(2015) Tugce Bilgin Sonay et al.   BMC GENOMICS

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

(2015) Jacques De Grève et al.   LUNG CANCER

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis

(2014) K Tsuta et al.   BRITISH JOURNAL OF CANCER

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

(2014) Samantha E. Bowyer et al.   MELANOMA RESEARCH

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastatic Rhabdoid Meningioma withBRAFV600E Mutation and Good Response to Personalized Therapy: Case Report and Review of the Literature

(2014) Oz Mordechai et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R–Mutated Melanoma

(2013) Philippe Bahadoran et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

(2013) Grit S. Herter-Sprie et al.   Frontiers in Oncology

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens

(2012) Shawn E. Yost et al.   NUCLEIC ACIDS RESEARCH

Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges

(2011) L. E. MacConaill et al.   Cancer Discovery

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome

(2009) George Poulogiannis et al.   HISTOPATHOLOGY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-solid oncogenes in solid tumors:EML4-ALKfusion genes in lung cancer

(2008) Hiroyuki Mano   CANCER SCIENCE

Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

(2008) Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of microsatellite instability in colorectal carcinoma by microfluidic-based chip electrophoresis

(2008) M Odenthal et al.   JOURNAL OF CLINICAL PATHOLOGY